GlassScriptPhysician profile
Robert D Shedden
NPI 1144284951
$507.28
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Neuromusculoskeletal Medicine, Sports Medicine
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $140 · 2021: $41.88.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $124.45 | 2019-2020 | |
| Tactile Systems Technology INC | $98.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.50 | 2019 | |
| Amgen INC. | $48.61 | 2019-2020 | |
| Eisai INC. | $33.35 | 2020 | |
| Collegium Pharmaceutical, INC. | $27.65 | 2020-2021 | |
| Biodelivery Sciences International, INC. | $25.10 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.12 | 2020 | |
| Daiichi Sankyo INC. | $15.33 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $13.63 | 2020 | |
| Horizon Therapeutics Plc | $13.13 | 2019 | |
| Pfizer INC. | $12.76 | 2021 | |
| Allergan, INC. | $12.57 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Shedden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.